This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
A blood biomarker for Alzheimer's disease may help estimate a cognitively healthy person's risk of developing mild cognitive impairment or dementia over the next five or 10 years, according to a new Mayo Clinic study in JAMA Neurology.
The approach combines a blood measure of phosphorylated Tau 217 (p-tau217), a biomarker associated with Alzheimer's disease, with age, sex and genetic risk to estimate a person's future risk of cognitive impairment. Higher p-tau217 levels and older age were associated with greater risk.
"The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology," says Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher and first author of the study.
The study builds on previous Mayo Clinic research that used PET brain scans to measure amyloid, a protein that accumulates in the brain in Alzheimer's disease, and predict future cognitive impairment. The new work applies a similar approach using a blood biomarker, which is less invasive and potentially more scalable.
Researchers analyzed 1,644 cognitively unimpaired participants in the Mayo Clinic Study of Aging and 534 participants in the Alzheimer's Disease Neuroimaging Initiative. Participants were ages 60 to 90 and had p-tau217 blood measurements, genetic testing and repeated cognitive assessments over time.
Using the Mayo Clinic Study of Aging data, researchers estimated the likelihood of developing mild cognitive impairment (MCI) or dementia within five and 10 years.
Source link







